GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HE3286

Company
Harbor Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00555451

    Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

    Not yet reported Harbor Therapeutics 66 participants Est. completion 2009-09 2 sites
    Other conditions: Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00628433

    Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

    Not yet reported, Not yet reported Harbor Therapeutics 27 participants Est. completion 2009-05 10 sites Stand-alone
    Other conditions: Ulcerative Colitis
    View official trial listing →
  • Completed NCT NCT00694057

    Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

    Not yet reported Harbor Therapeutics 164 participants Est. completion 2010-01 22 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00712114

    Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

    Not yet reported, Not yet reported Harbor Therapeutics 14 participants Est. completion 2009-07 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT00991107

    A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

    Not yet reported Harbor Therapeutics 5 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: Insulin Resistance
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.